Recently, kinase inhibitor such as Crizotinib for ALK fusions has shown therapeutic efficacy in NSCLC patients carrying other rearrangements, including ROS1 (c-ros oncogene 1), RET (rearranged during transfection), MET amplification and MET exon 14 deletion22. This evidence concerns the gene ALK and non-small cell lung carcinoma.